These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 11050699)

  • 1. Pharmacodynamic study of low molecular weight dermatan sulphate (Desmin) after a single subcutaneous administration in patients with renal insufficiency.
    Saivin S; Boneu B; Ducret F; Pourrat J; Palazzini E; Zamboni W; Duchêne P; Houin G
    Arzneimittelforschung; 2000 Sep; 50(9):821-6. PubMed ID: 11050699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers.
    Harenberg J; Jeschek M; Acker M; Malsch R; Huhle G; Heene DL
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):49-56. PubMed ID: 8845462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic characteristics of low-molecular-weight dermatan sulphate after subcutaneous administration in acute myocardial infarction.
    Traini AM; Cervi V; Melandri G; Palazzini E; Zamboni V; Semprini F; Candiotti N; Branzi A
    J Int Med Res; 1994; 22(6):323-31. PubMed ID: 7895895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of LMW dermatan sulphate: long-term persistence of intact material.
    Dawes J
    Thromb Haemost; 1993 Apr; 69(4):339-43. PubMed ID: 8497846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparin is responsible for the anti-Xa activity of Desmin 370.
    Brieger D; Dawes J
    Thromb Haemost; 1996 Feb; 75(2):286-91. PubMed ID: 8815578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of Desmin, a low molecular weight dermatan sulfate, after subcutaneous administration to healthy volunteers.
    Miglioli M; Pironi L; Ruggeri E; Serra C; Zamboni V; Barbanti M; Canova N; Calanni F; Milani MR; Palazzini E
    Int J Clin Lab Res; 1997; 27(3):195-8. PubMed ID: 9352383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human pharmacokinetics and pharmacodynamics of MF 701 dermatan sulfate administered by continuous intravenous infusion.
    Agnelli G; Cosmi B; Renga C; Federici F; Nenci GG; Houin G; Gianese F
    Thromb Haemost; 1990 Oct; 64(2):256-9. PubMed ID: 2270533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of dermatan sulfate after intravenous and intramuscular administration to healthy volunteers.
    Blardi P; Messa GL; Urso R; Di Perri T
    Int J Clin Pharmacol Res; 1993; 13(4):231-8. PubMed ID: 8150550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
    Liu ZQ; Wang L
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
    Sanderink GJ; Le Liboux A; Jariwala N; Harding N; Ozoux ML; Shukla U; Montay G; Boutouyrie B; Miro A
    Clin Pharmacol Ther; 2002 Sep; 72(3):308-18. PubMed ID: 12235452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
    Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1989 Jun; 61(3):357-62. PubMed ID: 2552604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency.
    Stöbe J; Siegemund A; Achenbach H; Preiss C; Preiss R
    Int J Clin Pharmacol Ther; 2006 Oct; 44(10):455-65. PubMed ID: 17063975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure.
    Gianese F; Nurmohamed MT; Imbimbo BP; Büller HR; Berckmans RJ; Ten Cate JW
    Br J Clin Pharmacol; 1993 Mar; 35(3):335-9. PubMed ID: 8471416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dermatan sulfate for anticoagulation in continuous renal replacement therapy.
    Vitale C; Verdecchia C; Bagnis C; Ganzaroli M; Giorcelli G; Marangella M
    J Nephrol; 2008; 21(2):205-12. PubMed ID: 18446715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.